Breast cancer is a leading cause of cancer -related morbidity and mortality, characterized by significant biological and molecular heterogeneity. Molecular subtypes —including luminal A, luminal B, HER2 - enriched, and triple -negative—inform prognosis and guide prec ision therapies. Despite advances with endocrine agents, HER2-targeted therapies, PARP inhibitors, and immune checkpoint inhibitors, therapeutic resistance remains a major challenge, driven by intratumoral heterogeneity, cancer stem cell plasticity, and tumor microenvironmental factors. Genomic profiling, liquid biopsies, combination and adaptive strategies, and next-generation antibody-drug conjugates are emerging to overcome resistance and optimize outcomes. Additionally, novel immunotherapies and artific ial intelligence (AI) –assisted decision -making support individualized treatment selection. This review summarizes recent advances, from molecular characterization to precision-guided interventions and strategies to counteract resistance, and emphasizes the integration of biological insights into personalized breast cancer management.
This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...
Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu et al.· Journal of Hematology & Onco...· 0 citations
A precision immunotherapy framework that integrates TNBC molecular subgroups, validated and dynamic biomarker models, rational combinations, resistance mechanisms, and emerging tools is proposed, including single-cell sequencing, spatial transcriptomics, multi-omics, and AI-assisted stratification to improve response d...
Shun-Hao Peng, Meng-Yao Qin, G. Song et al.· Frontiers in Immunology· 0 citations
A Dynamic Precision Oncology (DPO) framework is proposed that extends conventional precision oncology beyond baseline molecular profiling by integrating longitudinal assessment of tumor genomics, circulating tumor DNA, CA19-9, imaging, radiomics, and clinical characteristics and summarizes emerging strategies for overc...
Systemic therapy for breast cancer has evolved rapidly since 2020, driven by the expansion of targeted therapies, antibody-drug conjugates, and immunotherapy across biologic subtypes. The integration of tumor molecular profiling and germline testing has enabled increasingly personalized, biomarker-guided treatment stra...
S. Hurvitz· New England Journal of Medic...· 0 citations
Current treatment strategies across breast cancer subtypes are summarized, emerging therapies are highlighted, and the expanding APP role is emphasized.
W. Tobin· JAAPA : official journal of...· 0 citations
Introduction: Breast cancer is the most common malignancy in women and a major cause of mortality worldwide. Despite advances in treatment, therapeutic resistance and disease heterogeneity continue to limit the success of existing therapeutic approaches. Therefore, the identification of novel therapeutic targets has be...
Stela Novak, I. Kolarov-Bjelobrk, Marko Marjanovic et al.· Archive of Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
